Board Meeting

Vedanta Unaudited Consolidated Results for Quarter and Half Year Ended September 30, 2025

Vedanta Limited has announced its unaudited consolidated financial results for the second quarter and half year ended September 30, 2025. The company reported revenue...

Kalpataru Projects Reports Unaudited Financial Results for Q2 FY26

Kalpataru Projects International Limited announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2025. The company reported a total...

Shriram Finance Q2 FY26 Profit Rises 11.39%, Interim Dividend Declared

Shriram Finance (SFL) reported an 11.39% increase in profit after tax to Rs. 2,307.18 crores for Q2 FY26. The board declared an interim dividend...

GAIL (India) Limited Integrated Financial Results for Quarter and Half-Year Ended September 30, 2025

GAIL (India) Limited has announced its integrated financial results for the quarter and half-year ended September 30, 2025. The results, reviewed by the Board...

Maruti Suzuki India Q2 FY26 Results – Profit Surges Amid Strong Performance

Maruti Suzuki India reported strong Q2 FY26 results, with profit before tax reaching ₹43,393 million and total comprehensive income at ₹36,095 million. The company's...

Dr. Lal PathLabs Board Approves Bonus Issue, Dividend, and Stock Option Plan

Dr. Lal PathLabs' board has approved a bonus issue of 1:1, a ₹7 per share interim dividend, and a new employee stock option plan...

Sammaan Capital Unaudited Financial Results for Quarter Ended September 30, 2025

Sammaan Capital Limited (formerly Indiabulls Housing Finance Limited) has announced its unaudited consolidated financial results for the quarter ended September 30, 2025. The company...

Aptus Value Housing Finance Declares Interim Dividend & Approves Promoter Reclassification

Aptus Value Housing Finance India has declared an interim dividend of ₹2 per equity share (100% of face value) for the financial year 2025-26,...

Jubilant Pharmova Reports Q2 FY26 Results; API Business Sale Completed

Jubilant Pharmova reported its Q2 FY26 results, highlighting a revenue of ₹19,664 million. The company also completed the sale of its Active Pharmaceutical Ingredients...

Latest articles